KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Capital Expenditures: 2016-2024

Historic Capital Expenditures for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to $51.9 million.

  • Amneal Pharmaceuticals' Capital Expenditures fell 27.42% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.4 million, marking a year-over-year increase of 36.05%. This contributed to the annual value of $51.9 million for FY2024, which is 20.15% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Capital Expenditures of $51.9 million as of FY2024, which was up 20.15% from $43.2 million recorded in FY2023.
  • Over the past 5 years, Amneal Pharmaceuticals' Capital Expenditures peaked at $56.4 million during FY2020, and registered a low of $43.2 million during FY2023.
  • For the 3-year period, Amneal Pharmaceuticals' Capital Expenditures averaged around $47.2 million, with its median value being $46.4 million (2022).
  • In the last 5 years, Amneal Pharmaceuticals' Capital Expenditures dropped by 15.44% in 2021 and then rose by 20.15% in 2024.
  • Amneal Pharmaceuticals' Capital Expenditures (Yearly) stood at $56.4 million in 2020, then declined by 15.44% to $47.7 million in 2021, then declined by 2.77% to $46.4 million in 2022, then fell by 6.88% to $43.2 million in 2023, then grew by 20.15% to $51.9 million in 2024.